Inmune Bio Stock Analysis
INMB Stock | USD 4.90 0.03 0.62% |
INmune Bio is undervalued with Real Value of 7.94 and Target Price of 17.33. The main objective of INmune Bio stock analysis is to determine its intrinsic value, which is an estimate of what INmune Bio is worth, separate from its market price. There are two main types of INmune Bio's stock analysis: fundamental analysis and technical analysis.
The INmune Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and INmune Bio's ongoing operational relationships across important fundamental and technical indicators.
INmune |
INmune Stock Analysis Notes
About 29.0% of the company shares are held by company insiders. The book value of INmune Bio was currently reported as 1.74. The company recorded a loss per share of 2.1. INmune Bio had not issued any dividends in recent years. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about INmune Bio call the company at 858 964 3720 or check out https://www.inmunebio.com.INmune Bio Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. INmune Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding INmune Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
INmune Bio generated a negative expected return over the last 90 days | |
INmune Bio has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 155 K. Net Loss for the year was (30.01 M) with profit before overhead, payroll, taxes, and interest of 374 K. | |
INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41. | |
INmune Bio has a frail financial position based on the latest SEC disclosures | |
Roughly 29.0% of the company shares are held by company insiders | |
Latest headline from gurufocus.com: OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with ... |
INmune Bio Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to INmune Bio previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
7th of March 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
INmune Largest EPS Surprises
Earnings surprises can significantly impact INmune Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2019-03-29 | 2018-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2020-03-11 | 2019-12-31 | -0.25 | -0.22 | 0.03 | 12 | ||
2023-08-07 | 2023-06-30 | -0.4 | -0.36 | 0.04 | 10 |
INmune Bio Environmental, Social, and Governance (ESG) Scores
INmune Bio's ESG score is a quantitative measure that evaluates INmune Bio's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of INmune Bio's operations that may have significant financial implications and affect INmune Bio's stock price as well as guide investors towards more socially responsible investments.
INmune Stock Institutional Investors
Shares | Renaissance Technologies Corp | 2024-09-30 | 107.2 K | Northern Trust Corp | 2024-09-30 | 96.8 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 92.1 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 79.9 K | Corton Capital Inc. | 2024-09-30 | 76.1 K | Royal Bank Of Canada | 2024-09-30 | 62.1 K | Bank Of New York Mellon Corp | 2024-09-30 | 49.6 K | Xtx Topco Ltd | 2024-09-30 | 46.3 K | Citadel Advisors Llc | 2024-09-30 | 46.1 K | Blackrock Inc | 2024-06-30 | 812.9 K | Praetorian Pr Llc | 2024-09-30 | 780.8 K |
INmune Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 111.97 M.INmune Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.74) | (0.78) | |
Return On Capital Employed | (0.77) | (0.73) | |
Return On Assets | (0.53) | (0.55) | |
Return On Equity | (0.79) | (0.75) |
Management Efficiency
INmune Bio has return on total asset (ROA) of (0.4497) % which means that it has lost $0.4497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9896) %, meaning that it created substantial loss on money invested by shareholders. INmune Bio's management efficiency ratios could be used to measure how well INmune Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 7, 2024, Return On Tangible Assets is expected to decline to -0.78. The current year's Return On Capital Employed is expected to grow to -0.73. At present, INmune Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.56, whereas Total Assets are forecasted to decline to about 41.6 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.12 | 1.70 | |
Tangible Book Value Per Share | 1.20 | 0.91 | |
Enterprise Value Over EBITDA | 676.80 | 710.64 | |
Price Book Value Ratio | 5.31 | 5.57 | |
Enterprise Value Multiple | 676.80 | 710.64 | |
Price Fair Value | 5.31 | 5.57 | |
Enterprise Value | 177.1 M | 185.9 M |
INmune Bio has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Operating Margin (989.21) | Beta 1.852 | Return On Assets (0.45) | Return On Equity (0.99) |
Technical Drivers
As of the 7th of December, INmune Bio retains the Risk Adjusted Performance of (0.04), standard deviation of 4.35, and Market Risk Adjusted Performance of (0.13). INmune Bio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.INmune Bio Price Movement Analysis
The output start index for this execution was four with a total number of output elements of fifty-seven. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. INmune Bio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for INmune Bio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
INmune Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific INmune Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on INmune Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases INmune Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
INmune Bio Outstanding Bonds
INmune Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. INmune Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most INmune bonds can be classified according to their maturity, which is the date when INmune Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
US45782BAD64 Corp BondUS45782BAD64 | View | |
Dana 575 percent Corp BondUS235822AB96 | View | |
Installed Building Products Corp BondUS45780RAA95 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View |
INmune Bio Predictive Daily Indicators
INmune Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of INmune Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
INmune Bio Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 1st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 28th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 25th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 24th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 11th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
INmune Bio Forecast Models
INmune Bio's time-series forecasting models are one of many INmune Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary INmune Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About INmune Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how INmune Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling INmune shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as INmune Bio. By using and applying INmune Stock analysis, traders can create a robust methodology for identifying INmune entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (193.60) | (203.28) | |
Operating Profit Margin | (191.88) | (201.47) | |
Net Loss | (193.60) | (203.28) |
Current INmune Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. INmune analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. INmune analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
17.33 | Strong Buy | 6 | Odds |
Most INmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand INmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of INmune Bio, talking to its executives and customers, or listening to INmune conference calls.
INmune Stock Analysis Indicators
INmune Bio stock analysis indicators help investors evaluate how INmune Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading INmune Bio shares will generate the highest return on investment. By understating and applying INmune Bio stock analysis, traders can identify INmune Bio position entry and exit signals to maximize returns.
Begin Period Cash Flow | 52.2 M | |
Total Stockholder Equity | 38.1 M | |
Capital Lease Obligations | 516 K | |
Property Plant And Equipment Net | 414 K | |
Cash And Short Term Investments | 35.8 M | |
Net Invested Capital | 48.1 M | |
Cash | 35.8 M | |
200 Day M A | 8.2353 | |
50 Day M A | 5.3498 | |
Total Current Liabilities | 18.5 M | |
Stock Based Compensation | 7.4 M | |
Common Stock Shares Outstanding | 18 M | |
Free Cash Flow | -12 M | |
Operating Income | -29.7 M | |
Other Current Assets | 1.7 M | |
Accounts Payable | 7.9 M | |
Net Debt | -25.4 M | |
Depreciation | 224 K | |
Other Operating Expenses | 29.9 M | |
Non Current Assets Total | 17.1 M | |
Liabilities And Stockholders Equity | 57 M | |
Home Category | Domestic | |
Non Currrent Assets Other | 131 K |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Global Correlations Find global opportunities by holding instruments from different markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |